 <h1>Repaglinide Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of repaglinide include:</b> hypoglycemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to repaglinide: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, repaglinide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking repaglinide:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweats</li>
<li>coma</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>depression</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>headache</li>
<li>increased hunger</li>
<li>nausea</li>
<li>nightmares</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bladder pain</li>
<li>bloody or cloudy urine</li>
<li>difficult, burning, or painful urination</li>
<li>frequent urge to urinate</li>
<li>lower back or side pain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>bleeding gums</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>clay-colored stools</li>
<li>constipation</li>
<li>cough</li>
<li>darkened urine</li>
<li>diarrhea</li>
<li>difficulty with breathing</li>
<li>fever</li>
<li>general body swelling</li>
<li>general tiredness and weakness</li>
<li>indigestion</li>
<li>itching or rash</li>
<li>joint or muscle pain</li>
<li>light-colored stools</li>
<li>loss of appetite</li>
<li>nosebleeds</li>
<li>pains in the side, or abdomen, possibly radiating to the back</li>
<li>pale skin</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>unpleasant breath odor</li>
<li>upper right abdominal or stomach pain</li>
<li>vomiting</li>
<li>vomiting of blood</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of repaglinide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>difficulty with moving</li>
<li>ear congestion</li>
<li>loss of voice</li>
<li>muscle stiffness</li>
<li>pain in the joints</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>tightness of the chest</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Acid or sour stomach</li>
<li>belching</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>cough producing mucus</li>
<li>heartburn</li>
<li>indigestion</li>
<li>weight gain</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss or thinning of the hair</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to repaglinide: oral tablet</i></p><h3>General</h3><p>The most frequently reported adverse reactions were changes in blood glucose levels; the occurrence of these reactions was dependent on individual factors such as dietary habits, dose, exercise, and stress.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (up to 31%)<sup>[Ref]</sup></p><p>In 12 to 24 week clinical trials, hypoglycemia occurred in 31% of patients receiving this drug compared to 7% of placebo-treated patients.  In 1 year trials, hypoglycemia occurred in 16% of patients receiving this drug compared to 19% and 20% of glipizide and glyburide patients, respectively.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular events were evaluated in trials comparing this drug to sulfonylureas.  Serious cardiovascular events including ischemia with this drug were higher at 4% than for sulfonylurea drugs (3%).  No excess mortality was associated with this increase.  Selected cardiovascular events including hypertension, abnormal EKG, MI, arrhythmias, and palpitations were observed at 1% or less and no more frequently with this drug than with comparator drugs.  </p>
<p></p>
<p>Trials of this drug in combination with NPH insulin found 6 serious events of myocardial ischemia.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain, angina, serious cardiovascular events including ischemia</p>
<p><b>Frequency not reported</b>: Hypertension, abnormal EKG, MI, arrhythmias, palpitations<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergy</p>
<p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions such as rash, urticaria, and pruritus</p>
<p><b>Frequency not reported</b>: Anaphylactoid reactions<sup>[Ref]</sup></p><p>Anaphylactoid reactions were reported in less than 1% of patients.  Allergic skin reactions such as rash, urticaria, and pruritus have been observed.  There is no reason to suspect cross-allergenicity with sulfonylurea drugs due to the difference in chemical structure.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, constipation, vomiting, dyspepsia, tooth disorder </p>
<p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Paresthesia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Sinusitis, rhinitis, bronchitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Postmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Elevated liver enzymes</p>
<p><b>Postmarketing reports</b>: Severe hepatic dysfunction including jaundice and hepatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Thrombocytopenia, leukopenia</p>
<p><b>Postmarketing reports</b>: Hemolytic anemia<sup>[Ref]</sup></p><p>Thrombocytopenia or leukopenia have been reported in less than 1% of patients.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Refraction disorders have been known to result due to changes in blood glucose levels.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Blurred vision</p>
<p><b>Very rare</b> (less than 0.01%): Refraction disorder<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Alopecia, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about repaglinide</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: meglitinides</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Repaglinide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Prandin</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to repaglinide: oral tablet</i></p><h3>General</h3><p>The most frequently reported adverse reactions were changes in blood glucose levels; the occurrence of these reactions was dependent on individual factors such as dietary habits, dose, exercise, and stress.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia (up to 31%)<sup>[Ref]</sup></p><p>In 12 to 24 week clinical trials, hypoglycemia occurred in 31% of patients receiving this drug compared to 7% of placebo-treated patients.  In 1 year trials, hypoglycemia occurred in 16% of patients receiving this drug compared to 19% and 20% of glipizide and glyburide patients, respectively.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Cardiovascular events were evaluated in trials comparing this drug to sulfonylureas.  Serious cardiovascular events including ischemia with this drug were higher at 4% than for sulfonylurea drugs (3%).  No excess mortality was associated with this increase.  Selected cardiovascular events including hypertension, abnormal EKG, MI, arrhythmias, and palpitations were observed at 1% or less and no more frequently with this drug than with comparator drugs.  </p><p></p><p>Trials of this drug in combination with NPH insulin found 6 serious events of myocardial ischemia.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Chest pain, angina, serious cardiovascular events including ischemia</p><p><b>Frequency not reported</b>: Hypertension, abnormal EKG, MI, arrhythmias, palpitations<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Allergy</p><p><b>Uncommon</b> (0.1% to 1%): Allergic skin reactions such as rash, urticaria, and pruritus</p><p><b>Frequency not reported</b>: Anaphylactoid reactions<sup>[Ref]</sup></p><p>Anaphylactoid reactions were reported in less than 1% of patients.  Allergic skin reactions such as rash, urticaria, and pruritus have been observed.  There is no reason to suspect cross-allergenicity with sulfonylurea drugs due to the difference in chemical structure.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Nausea, diarrhea, constipation, vomiting, dyspepsia, tooth disorder </p><p><b>Postmarketing reports</b>: Pancreatitis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 11%)</p><p><b>Common</b> (1% to 10%): Paresthesia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia, back pain<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 16%)</p><p><b>Common</b> (1% to 10%): Sinusitis, rhinitis, bronchitis<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Postmarketing experience has included reports of severe hepatic dysfunction including jaundice and hepatitis.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Elevated liver enzymes</p><p><b>Postmarketing reports</b>: Severe hepatic dysfunction including jaundice and hepatitis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Thrombocytopenia, leukopenia</p><p><b>Postmarketing reports</b>: Hemolytic anemia<sup>[Ref]</sup></p><p>Thrombocytopenia or leukopenia have been reported in less than 1% of patients.<sup>[Ref]</sup></p><h3>Ocular</h3><p>Refraction disorders have been known to result due to changes in blood glucose levels.<sup>[Ref]</sup></p><p><b>Rare</b> (less than 0.1%): Blurred vision</p><p><b>Very rare</b> (less than 0.01%): Refraction disorder<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Postmarketing reports</b>: Alopecia, Stevens-Johnson syndrome<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about repaglinide</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>10 Reviews</li>
<li>Drug class: meglitinides</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Repaglinide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>